成人超重或肥胖药物比较效果:系统综述与网络荟萃分析
该系统综述与网络荟萃分析纳入262项随机对照试验(99 791名参与者),评估19种药物治疗成人超重或肥胖的效果。与仅生活方式干预相比,一年时替尔泊肽、CagriSema、口服司美格鲁肽等药物显著减重;但多数药物未显著改善生活质量,仅皮下司美格鲁肽与全因死亡率和心肌梗死风险降低相关。临床决策需权衡获益与危害。
要点
- 替尔泊肽一年减重14.9%,CagriSema减重14.8%,口服司美格鲁肽减重10.9%。
- 皮下司美格鲁肽与全因死亡率降低(RR 0.81)和心梗风险降低(RR 0.72)相关。
- 多数药物未显著改善生活质量,决策需权衡获益与危害。
核心结论
- 肥胖药物一年减重效果差异大,获益常伴随危害和停药增加;多数药物未显著改善生活质量,仅皮下司美格鲁肽显示心血管获益。
研究设计与样本
- 系统综述与网络荟萃分析,采用频率随机效应模型和贝叶斯剂量反应模型,GRADE分级和Cochrane偏倚风险工具。
- 共纳入262项随机对照试验(99 791名参与者),评估19种药物,随访12至172周。
主要发现
- 与仅生活方式干预相比,一年时替尔泊肽减重14.9%(95%CI -16.0%至-13.9%),CagriSema减重14.8%(-16.9%至-12.7%),口服司美格鲁肽减重10.9%(-12.7%至-9.1%)。
- 因不良事件停药风险最高为orforglipron、纳曲酮-安非他酮、利拉鲁肽、芬特明-托吡酯、CagriSema和口服司美格鲁肽(RR 1.9至4.2)。
- 疲劳风险增加尤其见于纳曲酮-安非他酮(RR 8.9;绝对增加331/1000人年)、orforglipron(RR 3.4;增加100/1000)和CagriSema(RR 3.2;增加92/1000)。
- 替尔泊肽减脂最多(25.7%),但瘦体重减少也最多(8.3%)。
- 皮下司美格鲁肽是全因死亡率(RR 0.81,95%CI 0.72至0.93)和心肌梗死(RR 0.72,95%CI 0.61至0.85)降低唯一相关药物;皮下司美格鲁肽(RR 0.43,95%CI 0.21至0.84)和替尔泊肽(RR 0.49,95%CI 0.27至0.88)降低心衰风险。
关键数值与推荐
- 减重:替尔泊肽-14.9%、CagriSema-14.8%、口服司美格鲁肽-10.9%、orforglipron-9.9%、皮下司美格鲁肽-9.8%、芬特明-托吡酯-8.1%(均 vs 仅生活方式干预,1年)。
- 因不良事件停药RR:orforglipron、纳曲酮-安非他酮、利拉鲁肽、芬特明-托吡酯、CagriSema、口服司美格鲁肽为1.9至4.2。
- 胃肠道事件RR:纳曲酮-安非他酮、口服司美格鲁肽、orforglipron、替尔泊肽为3.1至4.2。
- 生活质量:43项试验(45 663名参与者)中所有药物平均差异<5分(最小重要差异10分)。
临床怎么用
- 临床选择肥胖药物时需个体化权衡减重效果、不良事件停药风险和心血管获益。
- 皮下司美格鲁肽可考虑用于高心血管风险人群以降低死亡和心梗风险。
- 应预期胃肠道事件和疲劳等不良反应,尤其使用纳曲酮-安非他酮、orforglipron等药物时。
局限性
- 新兴药物(ecnoglutide、mazdutide、retatrutide)证据确定性极低至低。
- 心血管获益估计主要来自高风险人群的心血管结局试验。
- 生活质量改善均未超过最小重要差异,且部分药物缺乏长期数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To provide an up-to-date evidence summary about the comparative benefits and harms of drugs for adults with overweight or obesity to inform decision making for policymakers, payers, clinicians, and patients. DESIGN: Systematic review and network meta-analysis of 24 outcomes using frequentist random effects models and bayesian dose-response models, the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach, and the Cochrane Risk of Bias 2 tool. DATA SOURCES: Medline, Embase, and Cochrane Library, searched up to 12 November 2025. STUDY SELECTION: Randomised controlled trials of 12 weeks' duration or longer comparing one or more drugs with lifestyle modification, placebo, or another drug. RESULTS: This network meta-analysis comprised 262 trials (99 791 participants) evaluating 19 drugs with follow-up from 12 to 172 weeks. Compared with lifestyle modification alone, at one year, moderate to high certainty evidence shows substantial weight loss with tirzepatide (mean difference -14.9%, 95% confidence interval -16.0% to -13.9%), cagrilintide-semaglutide (CagriSema, -14.8%, -16.9% to -12.7%), oral semaglutide (-10.9%, -12.7% to -9.1%), orforglipron (-9.9%, -12.4% to -7.5%), subcutaneous semaglutide (-9.8%, -10.6% to -9.1%), and phentermine-topiramate (-8.1%, -9.7% to -6.5%). Emerging agents (ecnoglutide, mazdutide, retatrutide) may produce similar or greater reductions (13.1-14.6%; very low to low certainty). Moderate to high certainty evidence supports discontinuation because of adverse events to be highest with orforglipron, naltrexone-bupropion, liraglutide, phentermine-topiramate, CagriSema, and oral semaglutide (risk ratios from 1.9 to 4.2); gastrointestinal events were most increased with naltrexone-bupropion, oral semaglutide, orforglipron, and tirzepatide (risk ratios from 3.1 to 4.2). Fatigue risk increased, particularly with naltrexone-bupropion (risk ratio 8.9; absolute increase 331 per 1000 people over one year), orforglipron (3.4; 100 more per 1000), and CagriSema (3.2; 92 more per 1000). Tirzepatide reduced fat mass the most (by 25.7%) but also lean mass the most (by 8.3%). Subcutaneous semaglutide was the only drug associated with reduced all cause mortality (risk ratio 0.81, 95% confidence interval 0.72 to 0.93) and myocardial infarction (0.72, 0.61 to 0.85), with these estimates largely informed by cardiovascular outcome trials in high risk populations. Subcutaneous semaglutide (0.43, 0.21 to 0.84) and tirzepatide (0.49, 0.27 to 0.88) reduced heart failure risk. No drugs convincingly reduced kidney failure or improved quality of life (43 trials with 45 663 participants) beyond established minimally important differences (all mean differences <5 points; minimally important difference 10). Except for larger weight reductions in trials with longer duration (shown for subcutaneous semaglutide), subgroup analyses for drug dosages and key patient characteristics did not identify credible differences in relative effects of treatment. CONCLUSIONS: Obesity drugs produce variable weight loss at one year, with larger benefits generally accompanied by greater harms and discontinuation. Most agents do not improve quality of life meaningfully and few show cardiovascular benefits. Decisions in clinical practice should consider trade-offs between benefits and harms within the context of shared decision making. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42024507993.
引用
- Nong K, Shi Q, Xie X, et al. Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis. BMJ. 2026. PMID: 42419792. doi:10.1136/bmj-2026-372161
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。